Predictive Value of HAS-BLED Score Regarding Bleeding Events and Graft Survival following Renal Transplantation

Objective: Due to the high prevalence and incidence of cardio- and cerebrovascular diseases among dialysis-dependent patients with end-stage renal disease (ERSD) scheduled for kidney transplantation (KT), the use of antiplatelet therapy (APT) and/or anticoagulant drugs in this patient population is common. However, these patients share a high risk of complications, either due to thromboembolic or bleeding events, which makes adequate peri- and post-transplant anticoagulation management challenging. Predictive clinical models, such as the HAS-BLED score developed for predicting major bleeding events in patients under anticoagulation therapy, could be helpful tools for the optimization of antithrombotic management and could reduce peri- and postoperative morbidity and mortality. Methods: Data from 204 patients undergoing kidney transplantation (KT) between 2011 and 2018 at the University Hospital Leipzig were retrospectively analyzed. Patients were stratified and categorized postoperatively into the prophylaxis group (group A)—patients without pretransplant anticoagulation/antiplatelet therapy and receiving postoperative heparin in prophylactic doses—and into the (sub)therapeutic group (group B)—patients with postoperative continued use of pretransplant antithrombotic medication used (sub)therapeutically. The primary outcome was the incidence of postoperative bleeding events, which was evaluated for a possible association with the use of antithrombotic therapy. Secondary analyses were conducted for the associations of other potential risk factors, specifically the HAS-BLED score, with allograft outcome. Univariate and multivariate logistic regression as well as a Cox proportional hazard model were used to identify risk factors for long-term allograft function, outcome and survival. The calibration and prognostic accuracy of the risk models were evaluated using the Hosmer–Lemshow test (HLT) and the area under the receiver operating characteristic curve (AUC) model. Results: In total, 94 of 204 (47%) patients received (sub)therapeutic antithrombotic therapy after transplantation and 108 (53%) patients received prophylactic antithrombotic therapy. A total of 61 (29%) patients showed signs of postoperative bleeding. The incidence (p < 0.01) and timepoint of bleeding (p < 0.01) varied significantly between the different antithrombotic treatment groups. After applying multivariate analyses, pre-existing cardiovascular disease (CVD) (OR 2.89 (95% CI: 1.02–8.21); p = 0.04), procedure-specific complications (blood loss (OR 1.03 (95% CI: 1.0–1.05); p = 0.014), Clavien–Dindo classification > grade II (OR 1.03 (95% CI: 1.0–1.05); p = 0.018)), HAS-BLED score (OR 1.49 (95% CI: 1.08–2.07); p = 0.018), vit K antagonists (VKA) (OR 5.89 (95% CI: 1.10–31.28); p = 0.037), the combination of APT and therapeutic heparin (OR 5.44 (95% CI: 1.33–22.31); p = 0.018) as well as postoperative therapeutic heparin (OR 3.37 (95% CI: 1.37–8.26); p < 0.01) were independently associated with an increased risk for bleeding. The intraoperative use of heparin, prior antiplatelet therapy and APT in combination with prophylactic heparin was not associated with increased bleeding risk. Higher recipient body mass index (BMI) (OR 0.32 per 10 kg/m2 increase in BMI (95% CI: 0.12–0.91); p = 0.023) as well as living donor KT (OR 0.43 (95% CI: 0.18–0.94); p = 0.036) were associated with a decreased risk for bleeding. Regarding bleeding events and graft failure, the HAS-BLED risk model demonstrated good calibration (bleeding and graft failure: HLT: chi-square: 4.572, p = 0.802, versus chi-square: 6.52, p = 0.18, respectively) and moderate predictive performance (bleeding AUC: 0.72 (0.63–0.79); graft failure: AUC: 0.7 (0.6–0.78)). Conclusions: In our current study, we could demonstrate the HAS-BLED risk score as a helpful tool with acceptable predictive accuracy regarding bleeding events and graft failure following KT. The intensified monitoring and precise stratification/assessment of bleeding risk factors may be helpful in identifying patients at higher risks of bleeding, improved individualized anticoagulation decisions and choices of antithrombotic therapy in order to optimize outcome after kidney transplantation.

[1]  D. Seehofer,et al.  Influence of Multiple Donor Renal Arteries on the Outcome and Graft Survival in Deceased Donor Kidney Transplantation , 2021, Journal of clinical medicine.

[2]  T. Uemura,et al.  Is Continuing Anticoagulation or Antiplatelet Therapy Safe Prior to Kidney Transplantation? , 2021, Annals of transplantation.

[3]  C. Germer,et al.  Markedly increased risk of postoperative bleeding complications during perioperative bridging anticoagulation in general and visceral surgery , 2020, Perioperative Medicine.

[4]  D. Seehofer,et al.  Short and long-term metabolic outcomes in patients with type 1 and type 2 diabetes receiving a simultaneous pancreas kidney allograft , 2020, BMC Endocrine Disorders.

[5]  D. Seehofer,et al.  Effects of simultaneous pancreas-kidney transplantation and kidney transplantation alone on the outcome of peripheral vascular diseases , 2019, BMC Nephrology.

[6]  P. Reese,et al.  Association of Kidney Transplant Center Volume With 3-Year Clinical Outcomes. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  A. Ortiz,et al.  Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  S. Carugo,et al.  Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome , 2019, Heart and Vessels.

[9]  S. Bakker,et al.  Perioperative antithrombotic therapy does not increase the incidence of early postoperative thromboembolic complications and bleeding in kidney transplantation – a retrospective study , 2019, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  M. Banach,et al.  Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal , 2017, Pharmacological research.

[11]  M. Taljaard,et al.  Center Variation and the Effect of Center and Provider Characteristics on Clinical Outcomes in Kidney Transplantation: A Systematic Review of the Evidence , 2017, Canadian journal of kidney health and disease.

[12]  M. Selzner,et al.  Postoperative surgical‐site hemorrhage after kidney transplantation: incidence, risk factors, and outcomes , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  M. Fang,et al.  Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding , 2017, Seminars in Thrombosis and Hemostasis.

[14]  Deepak L. Bhatt,et al.  Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.

[15]  A. Speir,et al.  Obesity Increases Risk‐Adjusted Morbidity, Mortality, and Cost Following Cardiac Surgery , 2017, Journal of the American Heart Association.

[16]  G. Vlachopanos,et al.  Antithrombotic medications in dialysis patients: a double‐edged sword , 2017, Journal of evidence-based medicine.

[17]  S. Yusuf,et al.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.

[18]  M. Leung,et al.  Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study). , 2016, The Canadian journal of hospital pharmacy.

[19]  P. Stanich,et al.  Morbid Obesity is Associated with Increased Mortality, Surgical Complications, and Incremental Health Care Utilization in the Peri-Operative Period of Colorectal Cancer Surgery , 2016, World Journal of Surgery.

[20]  P. Stratta,et al.  Impact of pre-transplant antiaggregant and anticoagulant therapies on early hemorrhagic and cardiovascular events after kidney transplantation , 2015, Journal of Nephrology.

[21]  Carol Coupland,et al.  Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores , 2014, BMJ : British Medical Journal.

[22]  C. Merlo,et al.  The effect of center volume on the incidence of postoperative complications and their impact on survival after lung transplantation. , 2012, The Journal of thoracic and cardiovascular surgery.

[23]  D. Brennan,et al.  Delayed Graft Function in the Kidney Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  L. Cierpka,et al.  Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation. , 2011, Transplantation proceedings.

[25]  J. Tseng,et al.  Impact of center volume on outcomes of increased‐risk liver transplants , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[27]  K. Alexander,et al.  In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. , 2011, The American journal of cardiology.

[28]  G. Brock,et al.  Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? , 2011, Clinical transplantation.

[29]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[30]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[31]  Y. Becker,et al.  One Thousand Simultaneous Pancreas-Kidney Transplants at a Single Center With 22-Year Follow-Up , 2009, Annals of surgery.

[32]  N. Karidis,et al.  Vascular complications in renal transplantation: a single-center experience in 1367 renal transplantations and review of the literature. , 2009, Transplantation proceedings.

[33]  Sunil V. Rao,et al.  Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.

[34]  M. McCarter,et al.  Effect of body mass index on short-term outcomes after colectomy for cancer. , 2008, Journal of the American College of Surgeons.

[35]  M. Monreal,et al.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.

[36]  A. Torres,et al.  Retrospective analysis of surgical complications following cadaveric kidney transplantation in the modern transplant era. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[38]  S. Chadban,et al.  Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation. , 2005, Transplantation proceedings.

[39]  R. Ladurner,et al.  Technik der Multiorganentnahme , 2004 .

[40]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of surgery.

[41]  G. Friedman,et al.  Bleeding and Thrombosis in High-Risk Renal Transplantation Candidates Using Heparin , 2004, The Annals of pharmacotherapy.

[42]  S. Mulgaonkar,et al.  Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. , 2001, Transplantation.

[43]  S. Knechtle,et al.  Experience with 500 simultaneous pancreas-kidney transplants. , 1998, Annals of surgery.

[44]  R. Beyth,et al.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.

[45]  M. Fischereder,et al.  Early loss of renal transplants in patients with thrombophilia. , 1998, Transplantation.

[46]  F. Mills I, the donor. , 1985, Nursing mirror.

[47]  A. Day,et al.  Major bleeding in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[48]  K. Abbott,et al.  Thrombosis in end-stage renal disease. , 2004, Seminars in dialysis.